Global Statistics Representing Trigeminal Neuralgia (TN) Treatment Market
The global TN treatment market was valued at USD 169.30 Million in 2019 and is expected to grow at a CAGR of 5.1% during the forecast period, 2020-2029.
Market Overview: Rising Demand for TN Treatment Due to ExpandingGeriatric Population and the Increasing Prevalence of TN
Trigeminal neuralgia (TN) causes inflammatory conditions such as autoimmune disorders like Lyme disease, sarcoidosis, and multiple sclerosis. The increasing prevalence of TN among the growing geriatric population around the world is contributing to the growth of the trigeminal neuralgia treatment market.
- TN usually affects people older than 50 (American Association of Neuromuscular & Electrodiagnostic Medicine Organization)
- The incidence of TN is 12 per 100,000 persons annually (International Association for the Study of Pain)
- An estimated 150,000 people are diagnosed with TN every year (American Association of Neurological Surgeons)
- The incidence of new TN cases is approximately 12 per 100,000 people per year, as per the National Institute of Neurological Disorders and Strokes (NINDS) 2018 report
Trigeminal neuralgia’s etiology includes blood vessel obstruction, artery degeneration, myelin sheath invasion, and idiopathy. The condition is most often observed after age 40, and its incidence is greater among females.Further, youths suffering from multiple sclerosis are at a higher risk of developing TN. Among all regions, the trigeminal neuralgia treatment market in Asia-Pacific is expected to expand at a significant rate during the forecast period due to the region’s large patient pool.
Existence of a Robust Pipeline and Acceptance of New Medicines to Fuel Development of the Global Trigeminal Neuralgia Treatment Market in Years to Come
Research regarding the care of rare neurological disorders has been making advances. In line with this, the demand for technologically sophisticated tools for the storage and analysis of patient data and rapid integration is rising. Artificial intelligence, machine learning, digital biomedical biomarkers, and computational biology are expected to create opportunities enabling precise diagnosis and treatment.
Several pharmaceutical companies are significantly investing in TN treatment, and regulatory agencies have fastened the drug approval process for new biologics in TN treatment. During the forecast period, the existence of a robust pipeline and the acceptance of new medicines will fuel the development of the global trigeminal neuralgia treatment market. At present, industry players are focusing on innovative products that remove the need for medication and surgery in chronic pain due to TN. For example, PainShield (NanoVibronix) transmits slow release ultrasound to provide immediate pain relief for injury to the nerves and soft tissues; it is highly effective for TN pain relief and care.
Rising Awareness Regarding TN and the Subsequent Demand for TNDiagnostics and Treatment
Research organizations, such as the Trigeminal Neuralgia Association, the National Organization for Rare Disorders (NORD), the Facial Pain Association (FPA), the American Chronic Pain Association, the Brain & Life Organization, and the National Institute of Neurological Disorders and Stroke, are discovering mechanisms involved with chronic pain and trigeminal neuralgia, as well as novel diagnostic methods and treatments. The Facial Pain Research Foundation and Intl Trigeminal Neuralgia and Me (TNnME) organize the International Trigeminal Neuralgia Awareness Day on October 7 each year to raise awareness about the condition. Also, a collaborative task force was initiated by the European Association of Neurological Societies and the American Academy of Neurology to formulate general guidelines on TN treatment.
Trigeminal Neuralgia Treatment Market: Segmentation Overview
Treatment with Drugs:TheCarbamazepine Sub-Segment Was Valued at USD 53.44 Million in 2019 and Leads the Trigeminal Neuralgia Treatment Market
The demand for carbamazepine is projected to increase substantially in the coming years. Under various brand names such as Epitol, Carbatrol, Tegretol, and Tegretol XU, carbamazepine medications are used for treating a variety of diseases. The increasing cases of various types of seizures, bipolar disorders, and epilepsy areexpected to upsurge carbamazepine consumption. In particular, increasing epilepsy cases among the younger population have seen a rise in the drug’s consumption. Apart from this, those suffering from alcohol withdrawal disorders and psychotic disorders are also contributing to carbamazepine consumption. The FDA has approved the medical use of carbamazepine for epilepsy, manic episodes of bipolar disorders, and trigeminal neuralgia.
- In February 2019, Zydus Cadila received approval from the U.S. FDA to market Carbamazepine extended-release tablets for treating different types of seizures.
- In 2018, a clinical trial study was conducted to compare the efficacy and acceptability of carbamazepine (CBZ) plus betahistine mesilate tablets (BMT) (CBZ+BMT) and oxcarbazepine (OXC) plus BMT (OXC+BMT) in treating vestibular paroxysmia.
- In October 2016, U.S. FDA approved the Carnexiv (carbamazepine) injection by Lundbeck LLC as intravenous replacement therapy for oral carbamazepine formulations, giving it orphan drug designation.
- On the basis of an initial 15-patient study, an international group of investigators concluded that the sodium-channel blockers carbamazepine and phenytoin would be the prescribed first-line treatment in KCNQ2 encephalopathy cases.
Treatment with Surgeries:TheMicrovascular Decompression Sub-Segment to Register Substantial Growth with a CAGR of 5.4%during the Forecast Period
Microvascular decompression (MVD) is the most preferred surgical option to treat TN in younger patients. Its widespread adoptionis primarily attributable to its high success rates (> 90%); it is a permanent and curative procedure. MVD also causes the least damage to the trigeminal nerve and provides, on average, the longest pain-free periods and the best chance for the patient to be permanently off medication. MVD has a long-standing success rate of about 80% as a stand-alone treatment. The procedure requires an average hospital stay 2–3 days and 4–6 weeks to return to normal daily activities.
Treatment Providers: The Hospitals and Clinics Segment Dominates the Trigeminal Neuralgia Treatment Market
The availability of advanced treatment options, expertise in neuropathic pain, and reimbursement policies and developing healthcare infrastructure drive the prominence of hospitals as primary care providers for many health conditions. Hospitals offer a range of treatment options for controlling pain, including microvascular decompression and stereotactic radiosurgery, as well as rhizotomy and medication. Factors such as high patient turnaround, frequent readmissions, and large procedure volumes contribute to the segment’s significant share.Also, the shift toward early diagnosis, identification, and effective treatment of neurological disorders through minimally invasive approaches will create opportunities for the development of the hospital sector.
From a geographical perspective, the global trigeminal neuralgia treatment markethas been studied across five key regions, namely North America, Europe, Asia-Pacific, South America, and the Middle East and Africa.
North America Accounted for a 39% Value Share in 2019 and Expected to Dominate the Global Trigeminal Neuralgia Treatment Market throughout the Forecast Period
The expanding geriatric population and the increasing prevalence of TN contribute to the North America trigeminal neuralgia treatment market. An estimated 10,000–15,000 new cases of TN occur each year in the U.S., as per the National Organization for Rare Disease (NORD). Growing awareness associated with the early diagnosis and treatment of rare neurological disorders, supportive reimbursement policies, and R&D advances are leading the regional market development.
Potential drug candidates and their expected approvals in the coming years will stimulate the regional market. Furthermore, greater healthcare penetration and high healthcare expenditure in the U.S. and Canada also drive the trigeminal neuralgia treatment market, witha high concentration of pharmaceutical firms engaged in R&D of novel drugs for TN treatment leading developments.
- Biogen, a U.S. firm, is currently developing a drug named BIIB074 (vixotrigine) for TN treatment; It is in the pipeline, in phase 2.
- Vixotrigine is a state- and use-dependent, Nav1.7 channel blocker that also inhibits other voltage-gated sodium channels
- Biohaven Pharmaceuticals in the U.S.has two drugs, namely Rimegepant and Placebo, in clinical trials for TN treatment. It is currently in phase 2, and the estimated study completion date is December 31, 2020. Rimegepant has been designed as a selective and potent small molecule antagonist of CGRP receptor. CGRP neuropeptide is associated with neuronal sensitization and neuropathic pain.
Favorable reimbursement programs in the U.S. and Canada enhance TN treatment adoption. Further, significant development in the medical sector and augmented research institutes for improved YN treatmentalso contribute to regional growth. Proactive government policies that support neurological diagnostics can fuel faster market growth in the coming years. For example, the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health-NIH, the American Chronic Pain Association (ACPA), and the American Association of Neurological Surgeons, works on alleviating the global burden of neurological diseases by implementing regulatory policies, reviewing neurological diagnosis and therapeutic solutions, and developing work prospects for neuroscience research.
Asia-Pacific Trigeminal Neuralgia Treatment Market Expected to Register the Fastest Growth with a CAGR of 6.9%during the Forecast Period
The prevalence of TN is relatively high in Asia-Pacific; thus, the demand for treatment options is expected to rise at a significant pace in the coming years. As per a survey by Omics International, an estimated 4,458,090 people suffer from TN in China, i.e. 2.6% of the total population. High unmet medical needs, coupled with exponentially increasing R&D investments in healthcare and rising healthcare spending, in developing economies, such as India and China, represent opportunities for market players in the trigeminal neuralgia care market.
Leading players in Asia-Pacificare signing agreements with local drug manufacturers to develop technologically advanced products. In addition, the strong distribution network in pharma-emerging nations is also supporting the regional market. Thenumber of policy programs in the region is also projected to increase during the forecast period.
Increasing Healthcare Expenditure, Rising R&D Investments, and a Large Geriatric Population Foster the Trigeminal Neuralgia Treatment Market in Latin America and the Caribbean
In Latin America and the Caribbean, an estimated 71 million people are aged 60 and older, representing 11.2% of the population. The figure is expected to rise to around 100.5 million by 2025 and some 183.7 million by 2050, as per the estimations by the Latin American and Caribbean Demographic Centre (CELADE). Increasing healthcare expenditure, rising R&D investments, and a better understanding of the nature of rare neurological disorders are all driving market development in the region.
- GlaxoSmithKline plc
- Pfizer Inc.
- Trigemina, Inc.
- Novartis Pharmaceuticals Corporation
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals, Inc.
- Apotex Inc.
- Reddy’s Laboratories
- In November 2019, China Medical System signed a licensing agreement with Sun Pharma Advanced Research for the development and commercialization of levetiracetam in China, Hong Kong, Macau, and Taiwan
- In December 2018, the FDA approved Sun Pharma’s Elepsia XR (levetiracetam) extended-release tablets as adjunctive therapy for the treatment of partial-onset seizures in patients 12 years of age and older
Trigeminal Neuralgia Treatment Market: Segmentation
By Treatment Type
- Microvascular decompression
- Stereotactic radiosurgery
- Percutaneous procedures
By Treatment Provider
- Hospitals and clinics
- Ambulatory surgery centres
- The U.K.
- The Rest of Europe
- Southeast Asia
- The Rest of Asia-Pacific
- The Rest of South America
The Middle East and Africa
- The GCC Countries
- South Africa
- The UAE
- The Rest of MEA